Neumora Therapeutics Inc (NASDAQ: NMRA) on Monday, soared 9.50% from the previous trading day, before settling in for the closing price of $2.21. Within the past 52 weeks, NMRA’s price has moved between $1.83 and $21.00.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The company achieved an average annual earnings per share of 55.97%. With a float of $55.17 million, this company’s outstanding shares have now reached $160.48 million.
Let’s determine the extent of company efficiency that accounts for 124 employees. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Neumora Therapeutics Inc (NMRA) Insider Activity
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Neumora Therapeutics Inc is 65.85%, while institutional ownership is 29.81%. The most recent insider transaction that took place on Oct 18 ’24, was worth 239,319. In this transaction Director of this company sold 14,049 shares at a rate of $17.03, taking the stock ownership to the 20,100 shares. Before that another transaction happened on Oct 17 ’24, when Company’s Director sold 7,739 for $17.01, making the entire transaction worth $131,643. This insider now owns 20,100 shares in total.
Neumora Therapeutics Inc (NMRA) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around 55.97% per share during the next fiscal year.
Neumora Therapeutics Inc (NASDAQ: NMRA) Trading Performance Indicators
Neumora Therapeutics Inc (NMRA) is currently performing well based on its current performance indicators. A quick ratio of 10.98 was reported for the most recent quarter.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.85, a number that is poised to hit -0.44 in the next quarter and is forecasted to reach -1.61 in one year’s time.
Technical Analysis of Neumora Therapeutics Inc (NMRA)
Looking closely at Neumora Therapeutics Inc (NASDAQ: NMRA), its last 5-days average volume was 7.14 million, which is a drop from its year-to-date volume of 14.77 million. As of the previous 9 days, the stock’s Stochastic %D was 5.18%. Additionally, its Average True Range was 0.99.
During the past 100 days, Neumora Therapeutics Inc’s (NMRA) raw stochastic average was set at 3.84%, which indicates a significant decrease from 6.06% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 698.79% in the past 14 days, which was higher than the 276.59% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $9.62, while its 200-day Moving Average is $11.04. However, in the short run, Neumora Therapeutics Inc’s stock first resistance to watch stands at $2.53. Second resistance stands at $2.64. The third major resistance level sits at $2.84. If the price goes on to break the first support level at $2.22, it is likely to go to the next support level at $2.02. Should the price break the second support level, the third support level stands at $1.91.
Neumora Therapeutics Inc (NASDAQ: NMRA) Key Stats
Market capitalization of the company is 390.98 million based on 161,561K outstanding shares. Right now, sales total 0 K and income totals -235,930 K. The company made 0 K in profit during its latest quarter, and -72,550 K in sales during its previous quarter.
